A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
Phase III Study of Daratumumab/rHuPH20 NSC- 810307 + Lenalidomide or Lenalidomide as Post- Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma MM Using Minimal Residual Disease to Direct Therapy Duration DRAMMATIC Study
Expanded Access Program for belantamab mafodotin in Patients with Relapsed/Refractory Multiple Myeloma who are Refractory to a Proteasome Inhibitor, and an Immunomodulatory Agent, and an Anti-CD38 Antibody
Open-Label, Multicenter, Phase I Study to Assess the Safety of P-BCMA-101 in Subjects with Relapsed / Refractory Multiple Myeloma MM Followed by a Phase II Assessment of Response and Safety PRIME
A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants with Relapsed and/or Refractory Multiple Myeloma RRMM Who Have Normal and Varying Degrees of Impaired Renal Function DREAMM 12
Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant ASCENT: A Phase II Trial of Induction, Consolidation and Maintenance in Subjects with High Risk Smoldering Multiple Myeloma SMM
A Phase IB/IIA Multicenter, Open-Label, Dose Escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 as Monotherapy and in Combination with Other Treatments in Subjects with Multiple Myeloma